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Abstract
Monocytes are a key component of the innate immune system involved in the regulation of the adaptive immune response.
Previous studies have focused on apoptotic cell clearance abnormalities in systemic lupus erythematosus (SLE) monocytes.
However, whether SLE monocytes might express unique patterns of cytokine secretion in response to apoptotic cells is still
unknown. Here, we used monocytes from healthy controls and SLE patients to evaluate the production of TNF-a and TGF-b
in response to apoptotic cells. Upon recognition of apoptotic material, monocytes from healthy controls showed prominent
TGF-b secretion (mean 6 SD: 824.66144.3 pg/ml) and minimal TNF-a production (mean 6 SD: 32.662.1 pg/ml). In contrast,
monocytes from SLE patients had prominent TNF-a production (mean 6 SD: 302.26337.5 pg/ml) and diminished TGF-b
secretion (mean 6 SD: 685.96615.9 pg/ml), a difference that was statistically significant compared to normal monocytes
(p#10
26 for TNF-a secretion, and p=0.0031 for TGF-b, respectively). Interestingly, the unique cytokine response by SLE
monocytes was independent of their phagocytic clearance efficiency, opsonizing autoantibodies and disease activity. We
further showed that nucleic acids from apoptotic cells play important role in the induction of TNF-a by lupus monocytes.
Together, these observations suggest that, in addition to potential clearance defects, monocytes from SLE patients have an
abnormal balance in the secretion of anti- and pro-inflammatory cytokines in response to apoptotic cells. Since the
abnormal cytokine response to apoptotic material in SLE is not related to disease activity and opsonizing autoantibodies, it
is possible that this response might be an intrinsic property of lupus monocytes. The studies focus attention on toll-like
receptors (TLRs) and their downstream pathways as mediators of this response.
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Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoim-
mune disease characterized by an exuberant autoantibody
response to a wide variety of autoantigens. Disease is the result
of a cascade of events (induced by hormonal and environmental
factors) that occur on the background of an appropriate genetic
predisposition. In SLE, T and B-cell autoimmune responses result
in the generation of autoantibodies and immune complexes, along
with autoreactive T cells, which together cause pathology in
several target organs, including skin, blood vessels, lung and
kidney [1]. Defining the mechanisms underlying SLE initiation,
flares, and damage remains a high priority. The observation that
lupus autoantigens are selectively clustered in apoptotic surface
blebs initially focused attention on apoptosis as an important
pathway, upstream of inflammatory processes, which may be
relevant in initiating and propagating SLE [2,3].
In tissues, apoptotic cells are rapidly engulfed by macrophages
in the early phase of apoptotic cell death, and this uptake is
associated with secretion of anti-inflammatory cytokines, such as
TGF-b and IL-10, decreased secretion of IL-12 and TNF-a and
failure to upregulate co-stimulatory molecules [4–8]. Thus, the
early and efficient recognition and engulfment of apoptotic cells
has been proposed to be necessary to induce tolerance to
autoantigens. Although cumulative evidence from experimental
animal models has demonstrated that adequate apoptotic cell
clearance plays a role in mediating tolerance to apoptotic cells and
preventing autoimmunity [9–16], in human SLE, the possible
pathogenic consequences of an abnormal interaction between
apoptotic material and phagocytic cells remains unclear. Persua-
sive but indirect evidence suggests that patients with SLE have
impaired phagocytosis of apoptotic cells [17–20], but whether the
phagocytic defect is intrinsic to their macrophages, or acquired as
result of the abnormal inflammatory lupus environment (i.e.
cytokines and/or opsonizing molecules) is still unclear [21,22].
Paradoxically, lupus autoantibodies facilitate apoptotic cell
clearance and interestingly, trigger TNF-a release by macrophages
isolated from healthy donors [23]. However, whether SLE
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response to apoptotic cells has still to be defined.
In this study, we demonstrate that monocytes from SLE patients
have an abnormal balance in the secretion of anti- and pro-
inflammatory cytokines in response to apoptotic cells. Interesting-
ly, this cytokine response is independent of the phagocytic
clearance efficiency, the presence of opsonizing autoantibodies,
and lupus disease activity, and it is associated to the presence of
nucleic acids in the apoptotic cell milieu. These findings provide
novel insights into the pathogenic interface between lupus
monocytes and apoptotic cells, and might offer a mechanistic
explanation into the unexpected benefit that blocking TNF-a
activity has had in the treatment of patients with SLE. In addition,
since the abnormal cytokine response to apoptotic material in SLE
is not related to disease activity, it is possible that these findings
may suggest a primary defect (either genetic or epigenetic) in the
immunomodulatory response to apoptotic cells by lupus mono-
cytes.
Results
Lupus monocytes produce a pro-inflammatory pattern of
cytokine secretion in response to apoptotic cells
In tissues and in vitro, apoptotic cells are rapidly engulfed by
macrophages and this uptake is associated with enhanced secretion
of TGF-b and minimal production of TNF-a. To determine
whether SLE patients have unique patterns of cytokine secretion in
response to apoptotic material, we studied a large number of
patients (47 patients) and quantified the production of TGF-b and
TNF-a using a highly standardized and reproducible assay in
which control or SLE monocytes are co-incubated in the absence
or presence of dying cells in which apoptosis was induced by
ultraviolet B (UVB)-irradiation. Since autoantibodies enhance the
recognition and binding of apoptotic material [23], the assays were
performed using commercial human AB serum to directly address
the effect of apoptotic cells in monocytes in the absence of
autoantibodies. Thus, as previously described [4], upon recogni-
tion of apoptotic material, normal monocytes are characterized by
prominent TGF-b secretion (mean 6 SD: 824.66144.3 pg/ml)
and minimal TNF-a production (mean 6 SD: 32.662.1 pg/ml)
(Figure 1A and 1B, respectively). Interestingly, when monocytes
from SLE patients were exposed to apoptotic cells, the pattern of
cytokine secretion was strikingly different compared to control
cells. Thus, SLE monocytes were characterized by prominent
TNF-a production (mean 6 SD: 302.26337.5 pg/ml) and
diminished TGF-b secretion (mean 6 SD: 685.96615.9 pg/ml)
in response to apoptotic cells, a difference that was statistically
significant compared to normal monocytes (p#10
26 for TNF-a
secretion, and p=0.0031 for TGF-b, respectively) (Figure 1A and
1B, respectively). The basal production of TGF-b and TNF-a in
non-stimulated monocytes from controls (Figure 2A and 2B,
respectively) or SLE patients (Figure 2C and 2D, respectively) was
not statistically different, and neither apoptotic Jurkat cells alone,
monocytes incubated with live Jurkat cells, or live Jurkat cells
alone, produced and/or induced TGF-b (Figure 2A and 2C) and/
or TNF-a secretion (Figure 2B and 2D). Together, these data
demonstrate that the pattern of cytokine production generated by
monocytes upon recognition of apoptotic material is quite distinct
in patients with SLE compared to healthy monocytes. In addition,
it suggests that this response is not dependent on the presence of
opsonizing autoantibodies. It is noteworthy that the range of TGF-
b and TNF-a secretion by lupus monocytes was quite heteroge-
neous among the patients (Table 1). Thus, although 57% of the
SLE patients showed decreased production of TGF-b, the rest
showed normal (28%) or even high (15%) TGF-b secretion
compared to monocytes from healthy controls. In the case of
TNF-a, almost 90% of the lupus monocyes secreted TNF-a above
the normal range; the magnitude of this increase varied widely
among the patients. Interestingly, we found no association
between the production levels of TGF-b and TNF-a by lupus
monocytes and disease activity (determined by SLEDAI),
treatment, laboratory or clinical features, or demographic
characteristics in the patients (Table 1 and data not shown).
Taken together, these data strongly suggest that the abnormal
response of lupus monocytes to apoptotic cells may result from an
intrinsic property of the SLE monocyte itself.
Monocyte phagocytosis of apoptotic cells and TNF-a
production
Impaired clearance of apoptotic material has been proposed as
a mechanism underlying SLE pathogenesis. Although the decrease
in the production of TGF-b by SLE monocytes could be explained
by a defect in the recognition and engulfment of apoptotic cells,
this model does not explain the prominent production of TNF-a
observed in the patients. To gain insights into the relation between
apoptotic cell clearance and TNF-a secretion, we quantified the
apoptotic clearance capacity as well as TNF-a production in
controls and SLE patients. Thus, monocytes from 8 healthy
donors and 20 SLE patients were co-incubated in the presence of
CFSE-labeled live and apoptotic Jurkat cells, and phagocytosis was
determined by the percentage of cells positive for both CD14 and
CFSE (Figure S1). In the presence of live Jurkat cells, the
percentage of phagocytosis by control or SLE monoctyes was
minimal (range: 1.1–2.1% and 1.2–2.3%, respectively). In
contrast, both control and SLE monocytes were capable of
phagocytosing apoptotic Jurkat cells. However, the difference was
not statistically significant between the 2 groups (normal controls:
6.361.1% vs. SLE patients: 6.461.1%, p=0.70) (Table S1).
There was a wide range in TNF-a cytokine secretion in the SLE
patients (31–1000 pg/ml). However, we found no correlation
between the clearance capacity and TNF-a secretion by lupus
monocytes (p=0.267, R=0.26) (Figure 3). Taken together, these
data suggest that the abnormal secretion of TNF-a by lupus
monocytes is a process independent of apoptotic cell engulfment.
Nucleic acids from apoptotic cells are important
components in the induction of TNF-a secretion by SLE
monocytes
Beside the signals triggered through the interaction and/or
engulfment of apoptotic blebs by monocytes, it is possible that
other components from apoptotic cells might be responsible of
activating lupus monocytes. In this regard, there is increasing
evidence demonstrating that components containing nucleic acids
which are exposed to the surface and/or released from UVB-
irradiated cells dying by apoptosis are potent activators of the
innate immune response [2,24–28]. In order to address whether
RNA and/or DNA from the apoptotic cells might be involved in
the abnormal induction of TNF-a in SLE monocytes, monocytes
from patients with lupus were co-incubated with apoptotic cells, in
the absence or presence of RNase A, DNAse I, or both, and TNF-
a production in the supernatants was determined. In the presence
of apoptotic cells, monocytes from six consecutive SLE patients
showed TNF-a production with a variable range above the normal
limit observed in controls (i.e.$39 pg/ml). The presence of RNase
A or DNase I decreased the production of TNF-a by SLE
monocytes with a more prominent effect in the presence of both
nucleases (Figure 4) and interestingly, these results were more
Cytokine Response to Apoptotic Cells in Lupus
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(Figure 4, patients 5 and 6). In summary, these data demonstrate
that monocytes from patients with SLE have an abnormal pro-
inflammatory cytokine response to apoptotic material, and
strongly suggest that this response is mediated in part through
the recognition of nucleic acid containing components from
apoptotic cells.
Discussion
Systemic autoimmune diseases are a complex and heteroge-
neous group of disorders in which disease may reflect a self-
amplifying loop wherein antigen (possibly from apoptotic cells)
stimulates the immune system and induces specific inflammatory
effector pathways. The subsequent autoimmune phenotype may
depend on the source of autoantigen in concert with the specific
cytokine profile driven by the antigen. Thus, understanding these
effector pathways in unique autoimmune microenvironments
might have important implications in term of autoimmune disease
pathogenesis as well as the development of rational therapies. In
this report, we provide the first evidence that human lupus
monocytes have a unique pattern of cytokine secretion in response
to apoptotic cells, which is paradoxically characterized by high
TNF-a and low TGF-b production.
In SLE, there is cumulative evidence suggesting that apoptotic
cells are a source of autoantigens and/or adjuvant signals required
to initiate and/or propagate the autoimmune process [3,28].
Hypothetically, an impaired clearance of apoptotic corpses in
lupus might allow apoptotic cells to reach secondary necrosis and
subsequent release of intracellular contents. Antigen presenting
cells (APCs) may then acquire modified autoantigens and initiate
an autoimmune reaction. In this regard, special attention has been
focused on understanding the pathways involved in apoptotic cell
clearance and how these pathways might be affected in SLE [9–
20]. However, independently of the clearance capacity of lupus
phagocytes, the direct effect that apoptotic cells might have on the
function of lupus phagocytes has not been explored. In vitro,
phagocytes from healthy donors rapidly engulf apoptotic cells and
this uptake is associated with secretion of anti-inflammatory
cytokines, such as TGF-b and IL-10, decreased secretion of IL-12
and TNF-a[4–8]. Interestingly, when normal phagocytes are
exposed to apoptotic cells which have been previously opsonized
with antiphospholipid antibodies (a common SLE autoantibody),
there is a substantial increase in the recognition and uptake of
apoptotic cells by macrophages, accompanied by TNF-a secretion
[23]. In these studies, it is remarkable that lupus monocytes
express a potent inflammatory response to apoptotic material,
which is independent of opsonizing autoantibodies, clearance
efficiency and lupus disease activity. Although previous studies
have demonstrated that lupus monocytes produce substantially
higher levels of TNF-a upon stimulation with LPS or immune
complexes [29,30], this is the first study that shows that this
abnormal pattern of cytokine production can be induced by
apoptotic cells.
Thelackofassociation betweendiseaseactivityand production of
TNF-a by lupus monocytes is not surprising, particularly consid-
ering that although numerous reports agree that TNF-a expression
iselevatedinSLE,theassociationbetweenTNF-alevelsand disease
activity is less consistent [29,31–42]. Nevertheless, these findings
may suggest that the abnormal cytokine response observed in lupus
monocytes may represent an intrinsic property of the monocyte
Figure 1. Monocytes from patients with SLE have prominent production of TNF-a, but decreased production of TGF-b. Monocytes
obtained from healthy donors (n=13) or patients with SLE (n=47) were co-incubated in the presence of apoptotic Jurkat cells. After overnight
incubation, production of TGF-b (A) and TNF-a (B) were determined in the supernatants by ELISA. Data is shown as boxplots. Comparison of mean
cytokine secretion between groups was performed by Students t-test.
doi:10.1371/journal.pone.0017495.g001
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showed increased production of TNF-a in response to apoptotic
cells, it is likely that several predisposing factors related to TNF-a
production might be involved in this process. Thus, for example,
known genetic polymorphisms and/or epigenetic changes at the
TNF-a locus associated with SLE may contribute to this cytokine
Figure 2. Production of TGF-b and TNF-a by live or apoptotic Jurkat cells, non-stimulated monocytes and monocytes plus live
Jurkat cells. Monocytes from healthy donors (A & B) or patients with SLE (C & D) were incubated alone or in the presence of live Jurkat cells. In
addition, live or apoptotic Jurkat cells were incubated alone. After overnight incubation, production of TGF-b (A & C) and TNF-a (B & D) were
determined in the supernatants by ELISA.
doi:10.1371/journal.pone.0017495.g002
Table 1. Range of TNF-a and TGF-b secretion by lupus monocytes upon activation with apoptotic cells.
TGF-b (pg/ml) SLE N (%) SLEDAI score
1 P-value
,391.6 27 (57.4) 3.9 –
391.7–1257.5* 13 (27.7) 4.1 0.65
.1257.5 7 (14.9) 4.4 0.81
TNF-a (pg/ml) SLE N (%) SLEDAI score
1 P-value
26.3–38.9* 5 (10.6) 4.2 –
39–100 11 (23.4) 4.5 0.78
100–500 20 (42.5) 4.4 0.81
.500 11 (23.4) 4.5 0.83
*Normal range of cytokine secretion based on the mean 6 3SD from healthy controls.
1Mean SLEDAI scores were compared using t-test for comparison of means, reference group was the lowest secreting patients.
doi:10.1371/journal.pone.0017495.t001
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17495Figure 3. Pearson’s correlation between phagocytosis of apoptotic cells and TNF-a production by SLE monocytes. Control (Figure S1)
or SLE monocytes were co-incubated with CFSE-labeled apoptotic Jurkat cells. The percentage of cells positive for both CD14 and CFSE was used to
quantify phagocytosis of apoptotic Jurkat cells by monocytes. Only data from SLE monocytes is shown. Statistical analysis was performed with Stata
10 software (Stata Corporation, College Station, TX).
doi:10.1371/journal.pone.0017495.g003
Figure 4. TNF-a production by lupus monocytes in response to apoptotic cells is sensitive to RNase and DNase treatment. Monocytes
from six consecutive SLE patients were co-incubated with apoptotic Jurkat cells (UVJ) in the absence or presence of 5 mg/ml of RNase, 16 u/ml of
DNase, or both nucleases; and TNF-a production was determined by ELISA in the supernatants.
doi:10.1371/journal.pone.0017495.g004
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acids are important elements in apoptotic cells that are required for
the abnormal cytokine response by lupus monocytes, TLRs
(specifically TLR3, 7, 8 and 9) and their downstream pathways
may also play important role as mediators of this response. In this
regard, different murine models of lupus have been used to examine
the role of TLR9/7 in the response against self nucleic acids.
Interestingly, it has been found that TLR7 deficiency ameliorated
disease whereas TLR9 deletion resulted in more severe disease
[46,47]. Thus, it is possible that unique patterns of TLRs expression
may dictate the cytokine response induced by apoptotic cells. In
humans, the independent role of TLRs in lupus pathogenesis is less
clear [48–52]. In a recent study, it was found that the expression of
several TLRs (i.e. TLR-2, -3, -4, -5, -6, -8 and -9) were significantly
increased in SLE monocytes and interestingly, this pattern of
expression was independent of disease activity [52]. Furthermore,
genetic variants of TNFAIP3, a downstream component recruited
bytheTLRs and that restrictsNF-kB-dependent signaling,hasbeen
recently associated with SLE [53,54]. Thus, independently or
synergistically, these and other factors may contribute to the
magnitude of TNF-a production by lupus monocytes.
The pathogenic relevance of TNF-a in SLE is not yet clear.
While numerous reports agree that TNF-a is overexpressed in
patients with SLE [35–42] and MRL/lpr mice [55,56], this is not
universal. In some lupus models (e.g. the NZB x NZW F1 mouse),
reduced levels of TNF-a are observed, and replacement therapy
with recombinant TNF-a induces a significant delay in the
development of nephritis [57]. Additionally, there are well-
described associations association between TNF-a blockade and
the induction of lupus-like disease in humans [58,59]. One way to
define the role for TNF-a pathways in human SLE is to abrogate
TNF-a signaling and evaluate effects on disease activity. A recent
open-label study of infliximab (a drug which blocks TNF-a activity)
in 6 adults with moderately-active SLE reported promising results
[60]. In this regard, 3 patients with arthritis experienced remission
of joint symptoms and in 4 patients with nephritis, proteinuria
decreased within 1 week of infliximab administration and
diminished by .60% after 8 weeks of therapy. Interestingly,
antibodiestodsDNAand cardiolipinincreasedin4ofthe6 patients.
While TNF-a is generally considered a potent proinflammatory
cytokine, it also suppresses mitogen-induced B cell differentiation
and antibody production [61], an effect that might explain both the
anti-inflammatory benefit of TNF-a blockade observed in SLE, as
well as the increase in autoantibody production.
In summary, we provide evidence that monocytes from patients
with SLE have an abnormal production of TNF-a and TGF-b in
response to apoptotic cells. It is possible that these findings may
result from a primary defect (either genetic or epigenetic) in the
immunomodulatory response to apoptotic cells by lupus monocytes.
Methods
Ethics
The study was approved by The Johns Hopkins Medicine
Institutional Review Board (IRB) and all individuals signed an
informed consent.
Subject Selection
After obtaining IRB approval, 13 healthy controls (6 women
and 7 men, mean age 33.767.9 years) were recruited and
informed consent obtained. Forty-seven SLE patients (43 women
and 4 men, mean age 47.4610.7 years) were recruited through the
Johns Hopkins SLE cohort, an ongoing, NIH-funded prospective
study. There are well-established protocols and data collection
sheets completed at each patient visit, including laboratory tests
(complete blood count, sedimentation rate, autoantibodies,
complement levels) and clinical data.
Preparation of monocyte-enriched peripheral blood
mononuclear cells (PBMCs) and cytokine response to live
and apoptotic Jurkat cells
Monocytes were isolated as described [18,62] with some
modifications. Briefly, freshly isolated PBMCs were plated in
duplicates at 2610
6 cell/ml in RPMI containing 5% human AB
serum (Sigma-Aldrich), and allowed to adhere for one hour. Non-
adherent cells were removed through vigorous washing with RPMI,
leavingafinalconcentrationofapproximately1610
6 adherentcells,
which corresponded to 80–90% CD14+ cells as determined by flow
cytometry analysis (data not shown). Apoptotic Jurkat cells were
generated by UVB-irradiation as previously described [2] and
5610
6 live or apoptotic Jurkat cells were added per well to the
monocyte-enriched cells. In some experiments, monocytes and
apoptotic cells were co-incubated in the absence or presence of
5 mg/ml of RNase/DNase-free, 16 u/ml of DNAse-I/RNase-free,
or both nucleases (Roche Applied Science). In addition, some
monocyte samples were also used for apoptotic cell clearance assays
(see below). As controls, monocytes, apoptotic or live Jurkat cells
were incubated alone. After overnight incubation (16–18 hrs),
supernatants were collected, centrifuged to remove cellular
components, and TNF-a and TGF-b were determined using a
commercially available ELISA kit (R&D Systems). The optical
density ofeachsamplewasdeterminedusing a microplate readerset
to 450 nm (Biotrack, Pharmacia). Results were calculated from a
standard curve and reported in picograms of cytokine protein per
mL. Supernatants were assayed in duplicate and values were
expressed as means 6 standard deviations.
Apoptotic cell clearance assay
To quantify apoptotic cell clearance by human monocytes, we
established a FACS-based clearance assay. Thus, live and
apoptotic Jurkat cells were carboxy-fluorescein diacetate, succini-
midyl ester (CFSE)-labeled as describe by the manufacturer
(Sigma-Aldrich) and the equivalent to 5610
6 live and apoptotic
cells were co-incubated in duplicates with monocyte-enriched cells
prepared as above. As controls, monocytes were incubated alone.
After overnight incubation, non-adherent cells were removed by
vigorous washing and the adherent monocytes were then labeled
with CD14-PE (BD Biosciences, clone MwP9). The percentage of
cells positive for both CD14 and CFSE was used to quantitate
phagocytosis of apoptotic and live Jurkat cells by monocytes.
Statistical Analysis
P-values were determined based on Fisher’s exact test (for
binary variables), Pearson Chi Square statistic (for categorical
variables) and a two-sample t test (for continuous variables). In
order to account for multiple comparisons between groups, the
Bonferroni correction was applied.
Supporting Information
Figure S1 Apoptotic cell clearance assay. Monocytes from
healthy controls or SLE patients were co-incubated with live (B)
or apoptotic (C) CFSE-labeled Jurkat cells. As controls, monocytes
(A) or apoptotic Jurkat cells (D) were incubated alone. After
vigorous washings, the adherent cells (A, B, and C) or apoptotic
cells (D) were analyzed for CD14/CFSE positivity by FACS. We
have noted that CD14 is down-regulated in monocytes incubated
Cytokine Response to Apoptotic Cells in Lupus
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control is shown.
(TIF)
Table S1 The percentage of cells positive for both CD14 and
CFSE was used to quantify phagocytosis of apoptotic Jurkat cells
by monocytes. ID = Identification number; CFSE = carboxy-
fluorescein diacetate, succinimidyl ester.
(DOCX)
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